相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。SPOCK1 Is Regulated by CHD1L and Blocks Apoptosis and Promotes HCC Cell Invasiveness and Metastasis in Mice
Yan Li et al.
GASTROENTEROLOGY (2013)
Gefitinib resistance of cancer cells correlated with TM4SF5-mediated epithelial-mesenchymal transition
Mi-Sook Lee et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2012)
Dysregulation of Wnt/β-Catenin Signaling in Gastrointestinal Cancers
Bryan D. White et al.
GASTROENTEROLOGY (2012)
Slug Confers Resistance to the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
Tzu-Hua Chang et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2011)
Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer
Hyun-Jin Nam et al.
CANCER LETTERS (2011)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
Acquisition of Epithelial-Mesenchymal Transition Phenotype of Gemcitabine-Resistant Pancreatic Cancer Cells Is Linked with Activation of the Notch Signaling Pathway
Zhiwei Wang et al.
CANCER RESEARCH (2009)
Novel Mechanism of Lapatinib Resistance in HER2-Positive Breast Tumor Cells: Activation of AXL
Li Liu et al.
CANCER RESEARCH (2009)
Epithelial-Mesenchymal Transitions in Development and Disease
Jean Paul Thiery et al.
CELL (2009)
Novel markers for enterochromaffin cells and gastrointestinal neuroendocrine carcinomas
Justyna Leja et al.
MODERN PATHOLOGY (2009)
Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling
Shih-Min A. Huang et al.
NATURE (2009)
Lapatinib, a Dual EGFR and HER2 Tyrosine Kinase Inhibitor, Downregulates Thymidylate Synthase by Inhibiting the Nuclear Translocation of EGFR and HER2
Hwang-Phill Kim et al.
PLOS ONE (2009)
HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target
C. Gravalos et al.
ANNALS OF ONCOLOGY (2008)
The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines
Jin Won Kim et al.
CANCER LETTERS (2008)
Acquired Resistance to Small Molecule ErbB2 Tyrosine Kinase Inhibitors
Franklin L. Chen et al.
CLINICAL CANCER RESEARCH (2008)
Assessment of a HER2 scoring system for gastric cancer:: results from a validation study
M. Hofmann et al.
HISTOPATHOLOGY (2008)
Wnt signalling and its impact on development and cancer
Alexandra Klaus et al.
NATURE REVIEWS CANCER (2008)
Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy
M. Colleoni et al.
ANNALS OF ONCOLOGY (2008)
Downregulation of severa fibulin genes in prostate cancer
Agnes Wlazlinski et al.
PROSTATE (2007)
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer
Katrien Berns et al.
CANCER CELL (2007)
Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb®, GW572016) in an expanded panel of human normal and tumour cell lines
D. W. Rusnak et al.
CELL PROLIFERATION (2007)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer
Maurizio Scaltriti et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers
Wenle Xia et al.
CANCER RESEARCH (2007)
Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling
Rita Nahta et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3
Natalia V. Sergina et al.
NATURE (2007)
Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation
Judit Anido et al.
EMBO JOURNAL (2006)
A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer
Wenle Xia et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines
SE Witta et al.
CANCER RESEARCH (2006)
Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients
RL Yauch et al.
CLINICAL CANCER RESEARCH (2005)
Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition
S Thomson et al.
CANCER RESEARCH (2005)
Amplification of HER-2 in gastric carcinoma:: association with Topoisomerase IIα gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab
M Tanner et al.
ANNALS OF ONCOLOGY (2005)
Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016
WL Xia et al.
ONCOGENE (2004)
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
Y Nagata et al.
CANCER CELL (2004)
Epithelial-mesenchymal transitions in tumour progression
JP Thiery
NATURE REVIEWS CANCER (2002)
分享论文
